Phosphorylation of a full length amyloid-β peptide modulates its amyloid aggregation, cell binding and neurotoxic properties

Molecular BioSystems
Elaheh JamasbiGiuseppe D Ciccotosto

Abstract

Amyloid beta peptide (Aβ) is the major protein component of the amyloid plaques that are present in the brains of Alzheimer's disease (AD) patients. Aβ42 peptide is a known neurotoxic agent that binds to neurons and, under specific aggregation conditions, triggers cell death. Aβ peptide can undergo specific amino acid posttranslational modifications, such as phosphorylation, that are important for modulating its proteolytic degradation, aggregation, binding to lipid membranes and neurotoxic functions. Peptides phosphorylated at serine 8 in full-length Aβ42 (pAβ42) were synthesised and compared to native Aβ42 peptide. Their secondary structures, aggregation properties and interactions with plasma membranes of primary cortical neurons were investigated. The results revealed that pAβ42 has increased β-sheet formation with rapid amyloid formation in a synthetic lipid environment, which was associated with increased cellular binding but concomitant diminished neurotoxicity. Our data support the notion that phosphorylation of Aβ42 promotes the formation of amyloid plaques in the brain, which lack the neurotoxic properties associated with oligomeric species causing pathogenesis in AD.

References

Jan 1, 1996·Acta Neurologica Scandinavica. Supplementum·H Braak, E Braak
Oct 6, 2001·Journal of Peptide Science : an Official Publication of the European Peptide Society·A K TicklerJ D Wade
Aug 5, 2004·The Journal of Biological Chemistry·Giuseppe D CiccotostoKevin J Barnham
Aug 26, 2004·Protein and Peptide Letters·Anna K TicklerJohn D Wade
Oct 9, 2007·Biochimica Et Biophysica Acta·Tong-Lay LauFrances Separovic
Mar 28, 2009·Neurobiology of Aging·Giuseppe D CiccotostoRoberto Cappai
Jan 12, 2010·Journal of Alzheimer's Disease : JAD·Danielle G SmithKevin J Barnham
Feb 26, 2010·The Journal of Organic Chemistry·Bernadett BacsaC Oliver Kappe
Jun 8, 2012·Cold Spring Harbor Perspectives in Medicine·Colin L Masters, Dennis J Selkoe
Aug 30, 2012·Nature Methods·Caroline A SchneiderKevin W Eliceiri
Mar 13, 2014·Journal of the American Chemical Society·Nasrollah Rezaei-GhalehMarkus Zweckstetter
Jul 16, 2014·Molecular BioSystems·Alexandra A KulikovaAlexander A Makarov
Jul 18, 2014·Alzheimer's Research & Therapy·Markus P Kummer, Michael T Heneka
Jun 9, 2015·Biochimica Et Biophysica Acta·Elaheh JamasbiFrances Separovic
Nov 27, 2015·Journal of Neurochemistry·Metta K JanaGiuseppe D Ciccotosto
Jun 3, 2016·The Journal of Biological Chemistry·Nasrollah Rezaei-GhalehMarkus Zweckstetter

❮ Previous
Next ❯

Citations

Apr 6, 2021·Journal of Alzheimer's Disease : JAD·Makoto HashimotoEliezer Masliah
Jun 23, 2021·Biochemical Society Transactions·Sunnia RajputFrances Separovic
Jun 28, 2021·Current Opinion in Chemical Biology·Stuart P MoonMatthew R Pratt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.